Please login to the form below

Not currently logged in
Email:
Password:

Novartis Oncology head Bruno Strigini to retire

Will leave the Swiss pharma firm, and the industry, next year

Novartis Bruno StriginiThe head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry.

Citing personal reasons, the Swiss pharma firm said Strigini would step back from his place on its executive committee by December 31 and leave his current role in early 2018.

Novartis CEO Joseph Jimenez said: "I'd like to thank Bruno Strigini for his contributions and achievements. He has navigated the business unit through the Gleevec patent expiration and has led the successful integration of the GSK Oncology Product Portfolio acquired in 2015. I wish him the best for his future."

Strigini joined Novartis in 2014 from Merck & Co, where he spent nearly five years as president, Europe and Canada.

Prior to that he served in a similar role at Schering-Plough, before its acquisition by Merck in 2009.

19th December 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics